Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Ruxolitinib (Jakafi, approved in November 2011) and fedratinib (Inrebic, approved in August 2019) are the only two FDA-approved drugs for MF in the United States. Although Jakafi offers a therapeutic option, it is associated with high discontinuation rates and loss of response, and it does not address all MF symptoms. Therefore, significant market opportunity remains for safe and tolerable treatments that can manage the full spectrum of symptoms, as well as for treatment options for patients with baseline thrombocytopenia and anemia. This report explores the current prescribing practices for MF, the various factors driving treatment decisions, and the changes in prescribing that are expected to occur in the coming year.
- Which symptoms do surveyed hematologists cite as the most common among their MF patients? How do hematologists approach the management of MF patients? What factors drive physicians’ prescribing?
- What percentage of MF patients progress from one line of therapy to another based on severity? What is the treatment duration before progressing?
- Which drugs are the patient-share leaders in MF? How is Jakafi positioned in surveyed physicians’ treatment algorithms? What was the initial impact of Inrebic in the management of MF?
- What are prescribers’ estimates regarding patients’ compliance with current therapies?
- Myelofibrosis - Current Treatment - Detailed, Expanded Analysis (US)
Author(s): Kanika Ujla
Kanika Ujla is an Analyst for the Infectious, Niche, & Rare Diseases (INRD) team at Decision Resources Group. In this role she supports the team by conducting primary and secondary research across a range of antibacterial and antiviral indications as well as numerous niche and rare diseases. She holds experience in R&D, consulting, business research with healthcare and life sciences companies